Elanco Animal Health Incorporated (ELAN)
NYSE: ELAN · Real-Time Price · USD
12.82
+0.86 (7.19%)
At close: May 12, 2025, 4:00 PM
12.76
-0.06 (-0.47%)
After-hours: May 12, 2025, 7:42 PM EDT
Elanco Animal Health Revenue
Elanco Animal Health had revenue of $1.19B in the quarter ending March 31, 2025, a decrease of -1.00%. This brings the company's revenue in the last twelve months to $4.43B, up 1.42% year-over-year. In the year 2024, Elanco Animal Health had annual revenue of $4.44B with 0.50% growth.
Revenue (ttm)
$4.43B
Revenue Growth
+1.42%
P/S Ratio
1.43
Revenue / Employee
$468,466
Employees
9,450
Market Cap
6.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.44B | 22.00M | 0.50% |
Dec 31, 2023 | 4.42B | 6.00M | 0.14% |
Dec 31, 2022 | 4.41B | -353.00M | -7.41% |
Dec 31, 2021 | 4.76B | 1.49B | 45.64% |
Dec 31, 2020 | 3.27B | 200.00M | 6.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ELAN News
- 19 hours ago - Elanco: Deleveraging Takes Time - Seeking Alpha
- 5 days ago - Elanco Animal Health Incorporated (ELAN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide - Benzinga
- 5 days ago - Elanco Animal Health Reports First Quarter 2025 Results - PRNewsWire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect - Accesswire
- 7 days ago - Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Benzinga
- 7 days ago - Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown - PRNewsWire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out - Accesswire